Request Demo
Regulators Find Deficiences at Agila's Poland Plant, Suspend Manufacturing
20 Jan 2016
Poland’s Main Pharmaceutical Inspectorate has hit Mylan subsidiary Agila Specialties with a statement of GMP non-compliance following an inspection of the drugmaker's Warsaw-based manufacturing site.
Regulators noted 29 major deficiencies that put products at risk for microbial and particulate contamination, mostly sourounding the HVAC system and cleaning and maintenance.
Polish regulators have suspended manufacturing activities from the warsaw site as of December 9, 2015.
In February 2014
Agila initiated a recall
of an injectable general anesthesia due to the potential for small black particles, identified as paper shipper labels, to be present in individual vials; the potential for missing lot number and/or expiry date on the outer carton, and the potential for illegible/missing lot number and expiry on individual vials
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.